{
    "clinical_study": {
        "@rank": "51910", 
        "arm_group": [
            {
                "arm_group_label": "cefepime + Albumin", 
                "arm_group_type": "Experimental", 
                "description": "cefepime 1g iv 8 hourly + Albumin will be given for 2 days."
            }, 
            {
                "arm_group_label": "Imipenem + Albumin", 
                "arm_group_type": "Active Comparator", 
                "description": "Imipenem 1g iv 8 hourly + Albumin will be given for 2 days."
            }
        ], 
        "brief_summary": {
            "textblock": "1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of\n           Liver & Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous\n           Bacterial Peritonitis) by ascitic fluid examination at admission.\n\n        2. SBP (Spontaneous Bacterial Peritonitis) will be diagnosed in the presence of absolute\n           neutrophil count (ANC >250/mm3) with/without positive ascitic fluid culture and\n           Patients with SBP (Spontaneous Bacterial Peritonitis) included in the study will be\n           randomized to receive cefepime or imipenem.\n\n        3. However, other SBP (Spontaneous Bacterial Peritonitis) patients not included for\n           randomization will be given empirical therapy with 3rd generation cephalosporin\n           (ceftriaxone)."
        }, 
        "brief_title": "Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Spontaneous Bacterial Peritonitis (SBP).", 
        "condition_browse": {
            "mesh_term": "Peritonitis"
        }, 
        "detailed_description": {
            "textblock": "Baseline evaluation:\n\n      Baseline clinical, laboratory and disease severity parameters will be evaluated for each\n      study patient.\n\n        1. Etiology of cirrhosis.\n\n        2. Severity of liver disease. CTP (Child-Turcotte-Pugh) score MELD (Model for End-stage\n           Liver Disease) score MELD (Model for End-stage Liver Disease)-Na score IMSAA score\n\n        3. Decompensations/complications of CLD (Chronic Liver Disease) UGI bleed, Hepatic\n           encephalopathy, AKI (Acute Kidney Injury) etc.\n\n        4. Laboratory investigations:\n\n      Serum electrolytes Liver function tests Kidney function tests Pro calcitonin USG/CT abdomen\n      Complete blood counts Coagulation parameters Ascitic fluid analysis- TLC, DLC, Protein,\n      sugar, culture, SAAG. Chest X ray PA view HBsAg and Anti-HCV and other etiological workup as\n      available."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Cirrhotic Patients with SBP (Spontaneous Bacterial Peritonitis) having any of the\n        following risk factors would be considered as  'Difficult to Treat SBP'  and would be\n        included -\n\n          1. Nosocomial SBP: occurence of SBP (Spontaneous Bacterial Peritonitis) after 48 hours\n             of hospital admission, or\n\n          2. Prior ascitic fluid infection with 3rd generation cephalosporin resistant organism,\n             or\n\n          3. No response to treatment with 3rd generation cephalosporins after 48 hours.\n\n        Exclusion Criteria:\n\n          1. Age less than 18 years.\n\n          2. Cirrhotics with SBP (Spontaneous Bacterial Peritonitis) managed as outpatients.\n\n          3. Post liver transplant, HIV patients.\n\n          4. Patients on systemic chemotherapy, immunosuppressant drugs.\n\n          5. Growth of bacteria resistant to intervention drugs in ascitic fluid culture."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852630", 
            "org_study_id": "ILBS- SBP-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Imipenem + Albumin", 
                "description": "cefepime + Albumin will be given for 2 days", 
                "intervention_name": "cefepime + Albumin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cefepime + Albumin", 
                "description": "Imipenem + Albumin will be given for 2 days.", 
                "intervention_name": "Imipenem + Albumin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Imipenem", 
                "Cefepime"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of Liver & Biliary Sciences (ILBS)"
            }, 
            "investigator": {
                "last_name": "Ankur Jindal, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Comparative Open Label Study of Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure.", 
        "overall_contact": {
            "email": "ankur.jindal3@gmail.com", 
            "last_name": "Dr Ankur Jindal, MD", 
            "phone": "+91-9582670984"
        }, 
        "overall_official": {
            "affiliation": "Institute of Liver & Biliary Sciences (ILBS)", 
            "last_name": "Dr Ankur Jindal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome of the study is the Response to treatment in each intervention group. Response is defined as 25% reduction in ANC (Absolute Neutrophil Count) from baseline.", 
            "safety_issue": "No", 
            "time_frame": "2 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Survival", 
            "safety_issue": "Yes", 
            "time_frame": "15 days,1 month and 3 months"
        }, 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}